RxDoctor Payments Data

Vasily Rozenbaum, MD

Family Medicine · Jacksonville, FLNPI 1245727973

Payments from drug & device makers

$5,866in general payments, 2019–2025

Across 215 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$796
  • Novo Nordisk$623
  • Lilly USA, LLC$517
  • Axsome Therapeutics, Inc.$314
  • Pfizer$259
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,865100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,866 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$233,007
Medicare patients
357
Services billed
4,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$123,876
MounjaroTirzepatide88$109,618
FarxigaDapagliflozin Propanediol90$84,762
Xigduo XrDapaglifloz Propaned/Metformin43$38,149
JardianceEmpagliflozin19$27,890
XareltoRivaroxaban30$24,154
MyrbetriqMirabegron19$21,154
Synjardy XrEmpagliflozin/Metformin Hcl19$17,825
TrulicityDulaglutide16$13,972
Repatha SureclickEvolocumab18$12,836
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,211
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid81$8,256
Spiriva RespimatTiotropium Bromide11$6,806
Rosuvastatin Calcium328$5,691
Testosterone13$5,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$623$123,876104 claims
Lilly USA, LLCMounjaro, Trulicity$517$123,590104 claims
AstraZenecaFarxiga$796$84,76290 claims
Johnson & JohnsonXarelto$17$24,15430 claims
Astellas Pharma US IncMyrbetriq$62$21,15419 claims
GSKTrelegy Ellipta$225$12,21113 claims
AbbVieSynthroid$1,029$3,23242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →